Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Two-stage, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors

NCT04400383 is registered in ClinicalTrials.gov with CARsgen Therapeutics Co., Ltd. as lead sponsor.

NCT NCT04400383
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04400383 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Two-stage, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors
Lead sponsor
CARsgen Therapeutics Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
June 4, 2020
Completion date
September 28, 2023
Enrollment
62 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, pancreatic adenocarcinoma, solid tumor